Products
Zilovertamab Biosimilar Monoclonal Antibody (ROR1) for Research
Pre-Made Zilovertamab biosimilar, Whle mAb, Anti-ROR1 Antibody: Anti-NTRKR1/dJ537F10.1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-647-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Zilovertamab biosimilar, Whle mAb, Anti-ROR1 Antibody: Anti-NTRKR1/dJ537F10.1 therapeutic antibody |
| INN Name | Zilovertamab |
| Target | ROR1 |
| Format | Whle mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | University of California;Oncternal Therapeutics;Merck |
| Conditions Approved | na |
| Conditions Active | Breast cancers;Chronia lymphocytic leukemia;Mantle cell leukemia;Lymphoma |
| Conditions Discontinued | na |
| Development Tech | na |
About target - ROR1
1. Protein Inactive tyrosine-protein kinase transmembrane receptor ROR1
2. Gene ROR1
3. Organism Homo sapiens (Human)
Function
Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo (PubMed:25029443).
Receptor for ligand WNT5A which activate downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, PubMed:27162350).
In inner ear, crucial for spiral ganglion neurons to innervate auditory hair cells (PubMed:27162350).
